- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07915973
Impacto 2.0: Mobile Smoking Cessation Across Texas
Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas
This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Impacto 2.0 is a culturally adapted, bilingual (English and Spanish) smartphone-based smoking cessation intervention designed for Hispanic adults who smoke and have elevated anxiety sensitivity. The intervention includes smoking cessation content, psychoeducation, coping skills, and exercises designed to reduce anxiety sensitivity.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either Impacto 2.0 or the National Cancer Institute's quitSTART app. Participants in both conditions will receive study-provided nicotine replacement therapy and will use their assigned mobile application during an 8-week treatment period.
Participants will complete 4 weeks of pre-quit app engagement, with their quit day and nicotine replacement therapy start scheduled at Week 4, followed by 4 weeks of post-quit treatment. Study assessments will be completed at baseline, Week 4, Week 8, and Week 16. Smoking status will be assessed through self-report and remote biochemical verification using the CoVita iCOquit Smokerlyzer.
The primary outcome is biochemically verified 7-day point-prevalence smoking abstinence at Week 8. Secondary outcomes include smoking abstinence at Week 16 and changes in anxiety sensitivity, tobacco withdrawal, and craving.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michael J Zvolensky, Ph.D.
- Phone Number: 713-743-8056
- Email: mjzvolen@Central.UH.EDU
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77204
- RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
-
Contact:
- Angelica G. Duran, B.S
- Phone Number: 713-743-8056
- Email: agduran@cougarnet.uh.edu
-
Principal Investigator:
- Micheal J Zvolensky, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Self-identifies as Hispanic/Latino/a
- Currently resides in Texas
- Age 18 years or older
- Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
- Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
- Motivated to quit smoking
- Able to provide informed consent
- Has daily access to an iPhone or Android smartphone
- Fluent in English or Spanish
Exclusion Criteria:
- Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
- Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
- Current psychotherapy for anxiety or depression
- Concurrent use of medication for anxiety or depression
- Active suicidality (ideation, intent, and/or plan)
- Current psychosis
- Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
- Myocardial infarction within the past 2 weeks
- Uncontrolled high blood pressure
- Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Impacto 2.0
Participants will use the Impacto 2.0 smartphone application for 8 weeks. |
A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity. |
|
Active Comparator: quitSTART
Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks. |
The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Time Frame: Week 8
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Time Frame: Week 16
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 16
|
|
Tobacco Withdrawal
Time Frame: Baseline, Week 4, Week 8, and Week 16
|
Tobacco withdrawal will be assessed using the Minnesota Nicotine Withdrawal Scale (MNWS). |
Baseline, Week 4, Week 8, and Week 16
|
|
Tobacco Craving
Time Frame: Baseline, Week 4, Week 8, and Week 16
|
Tobacco craving will be assessed using the Questionnaire of Smoking Urges-Brief (QSU-B). |
Baseline, Week 4, Week 8, and Week 16
|
|
Anxiety Sensitivity
Time Frame: Baseline, Week 4, Week 8, and Week 16
|
Anxiety sensitivity will be assessed using the Short Scale Anxiety Sensitivity Index (SSASI). |
Baseline, Week 4, Week 8, and Week 16
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00006201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is no plan to make individual participant data (IPD) available to other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.